Golimumab can make it more difficult for your body to fight infections. Therefore, people with active infections should not take golimumab. If you have a fever, think you have an infection or have been prescribed an antibiotic, contact your healthcare provider. People who have had frequent infections in the past or a history of tuberculosis should discuss the use of golimumab with their healthcare provider.
Also contact your healthcare provider if you are having surgery as you may need to stop golimumab until you are healed and there is no sign of infection.
Golimumab has not been studied in pregnant people or lactating parents so its effect(s) on pregnant people or nursing babies are unknown. You should tell your doctor if you are pregnant or are planning to become pregnant. Because of the potential for adverse reactions in nursing infants, a decision should be made with your healthcare provider on whether or not to discontinue nursing or the medication, taking into account the importance of the drug to the lactating parent.
Anyone who has had a previous allergic reaction to golimumab should avoid the medication.
People with a history of cancer or nervous system problems, such as multiple sclerosis, should discuss the use of golimumab with their healthcare provider.
Golimumab may make a condition called congestive heart failure worse. Tell your doctor if you have congestive heart failure.
Before starting this medication, you will likely be tested for inactive (“latent”) tuberculosis (TB) and hepatitis B because golimumab can dampen the immune system and cause these infections to become active. If TB or hepatitis is found, it will need to be treated before you start golimumab.
Ideally, your vaccinations should be up to date prior to starting golimumab. If you have already started therapy with golimumab, your healthcare provider will likely recommend most inactive vaccines (e.g., influenza, pneumococcal). Live vaccines are not recommended due to risk of causing infection. Before receiving any vaccinations while taking golimumab, you should speak with your healthcare provider.